Found: 23
Select item for more details and to access through your institution.
Clinical Characteristics and Prognostic Factors in Primary Breast Diffuse Large BCell Lymphoma.
- Published in:
- Mediterranean Journal of Hematology & Infectious Diseases, 2022, v. 14, n. 1, p. 1, doi. 10.4084/MJHID.2022.066
- By:
- Publication type:
- Article
Serum miR‐146a level is a potential biomarker in predicting the outcome of diffuse large B‐cell lymphoma.
- Published in:
- Asia Pacific Journal of Clinical Oncology, 2023, v. 19, n. 5, p. e283, doi. 10.1111/ajco.13911
- By:
- Publication type:
- Article
Interim PET/CT result is the sole prognostic factor of survival in patients with advanced-stage diffuse large B-cell lymphoma: a subset analysis of a prospective trial.
- Published in:
- Journal of Radioanalytical & Nuclear Chemistry, 2021, v. 327, n. 1, p. 353, doi. 10.1007/s10967-020-07511-z
- By:
- Publication type:
- Article
Metabolism related gene signature predicts prognosis and indicates tumor immune infiltration in ovarian cancer.
- Published in:
- European Journal of Gynaecological Oncology, 2024, v. 45, n. 3, p. 37, doi. 10.22514/ejgo.2024.040
- By:
- Publication type:
- Article
Primary Tumor Resection Is Associated with Improved Survival in Stage IV Colorectal Cancer: An Instrumental Variable Analysis.
- Published in:
- Scientific Reports, 2015, p. 16516, doi. 10.1038/srep16516
- By:
- Publication type:
- Article
Anlotinib reversed resistance to PD-1 inhibitors in recurrent and metastatic head and neck cancers: a real-world retrospective study.
- Published in:
- Cancer Immunology, Immunotherapy, 2024, v. 73, n. 10, p. 1, doi. 10.1007/s00262-024-03784-5
- By:
- Publication type:
- Article
Development and Validation of Pretreatment Serum Total Bilirubin as a Biomarker to Predict the Clinical Outcomes in Primary Central Nervous System Lymphoma: A Multicenter Cohort Study.
- Published in:
- Cancers, 2023, v. 15, n. 18, p. 4584, doi. 10.3390/cancers15184584
- By:
- Publication type:
- Article
Prognostic significance of clinical characteristics and 18 Fluorodeoxyglucose-positron emission tomography/computed tomography quantitative parameters in patients with primary mediastinal B-cell lymphoma.
- Published in:
- Journal of International Medical Research, 2022, v. 50, n. 1, p. 1, doi. 10.1177/03000605211063027
- By:
- Publication type:
- Article
Radiotherapy followed by DICEP regimen in treatment of newly diagnosed, stage IE/IIE, extranodal NK/T‐cell lymphoma patients.
- Published in:
- Cancer Medicine, 2020, v. 9, n. 15, p. 5400, doi. 10.1002/cam4.3207
- By:
- Publication type:
- Article
Remote modulation of WWOX by an intronic variant associated with survival of Chinese gastric cancer patients.
- Published in:
- International Journal of Cancer, 2024, v. 154, n. 2, p. 307, doi. 10.1002/ijc.34703
- By:
- Publication type:
- Article
Imaging of Tumor Stroma Using <sup>68</sup>Ga-FAPI PET/CT to Improve Diagnostic Accuracy of Primary Tumors in Head and Neck Cancer of Unknown Primary: A Comparative Imaging Trial.
- Published in:
- Journal of Nuclear Medicine, 2024, v. 65, n. 8, p. 1, doi. 10.2967/jnumed.123.266556
- By:
- Publication type:
- Article
Imaging of Tumor Stroma Using <sup>68</sup>Ga-FAPI PET/CT to Improve Diagnostic Accuracy of Primary Tumors in Head and Neck Cancer of Unknown Primary: A Comparative Imaging Trial.
- Published in:
- Journal of Nuclear Medicine, 2024, v. 65, n. 3, p. 365, doi. 10.2967/jnumed.123.266556
- By:
- Publication type:
- Article
Imaging of Tumor Stroma Using <sup>68</sup>Ga-FAPI PET/CT to Improve Diagnostic Accuracy of Primary Tumors in Head and Neck Cancer of Unknown Primary: A Comparative Imaging Trial.
- Published in:
- Journal of Nuclear Medicine, 2024, v. 65, n. 2, p. 1, doi. 10.2967/jnumed.123.266556
- By:
- Publication type:
- Article
The Added Value of <sup>68</sup>Ga-FAPI-PET/CT in Patients with Head and Neck Cancer of Unknown Primary with <sup>18</sup>F-FDG Negative Findings.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 12, p. 1, doi. 10.2967/jnumed.121.262790
- By:
- Publication type:
- Article
The Added Value of <sup>68</sup>Ga-FAPI-PET/CT in Patients with Head and Neck Cancer of Unknown Primary with 18F-FDG Negative Findings.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 11, p. 1, doi. 10.2967/jnumed.121.262790
- By:
- Publication type:
- Article
The Added Value of <sup>68</sup>Ga-FAPI-PET/CT in Patients with Head and Neck Cancer of Unknown Primary with <sup>18</sup>F-FDG Negative Findings.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 10, p. 1, doi. 10.2967/jnumed.121.262790
- By:
- Publication type:
- Article
Endostar in combination with modified FOLFOX6 as an initial therapy in advanced colorectal cancer patients: a phase I clinical trial.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2015, v. 75, n. 3, p. 547, doi. 10.1007/s00280-014-2656-9
- By:
- Publication type:
- Article
Value of staging information provided by linear‐array endoscopic ultrasound for therapeutic response and prognosis prediction in gastric lymphoma.
- Published in:
- Digestive Endoscopy, 2021, v. 33, n. 6, p. 929, doi. 10.1111/den.13884
- By:
- Publication type:
- Article
Hexokinase II expression as a prognostic marker in diffuse large B-cell lymphoma: pre- and post-rituximab era.
- Published in:
- International Journal of Hematology, 2022, v. 116, n. 3, p. 372, doi. 10.1007/s12185-022-03358-0
- By:
- Publication type:
- Article
A phase I study of ridaforolimus in adult Chinese patients with advanced solid tumors.
- Published in:
- Journal of Hematology & Oncology, 2013, v. 6, n. 1, p. 1, doi. 10.1186/1756-8722-6-48
- By:
- Publication type:
- Article
Combined taxane, platinum, and cetuximab as a first‐line treatment for recurrent/metastatic head and neck squamous cell carcinoma: Retrospective study.
- Published in:
- Head & Neck, 2022, v. 44, n. 9, p. 2040, doi. 10.1002/hed.27085
- By:
- Publication type:
- Article
Four cycles of R-CHOP followed by two applications of rituximab based on negative interim PET/CT: an analysis of a prospective trial.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Combination of cetuximab and PP242 synergistically suppress the progression of wild-type KRAS colorectal carcinoma.
- Published in:
- OncoTargets & Therapy, 2015, v. 8, p. 3185, doi. 10.2147/OTT.S82453
- By:
- Publication type:
- Article